Clinical trial CA045-001
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
| Cancers | |
|---|---|
| Organ | Skin |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BMS - Bristol Myers Squibb int. |
| EudraCT Identifier | 2018-001423-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03635983 |
| Inclusion criteria | Stage III or IV, unresecable |
| Last update |